<div id="readability-page-1"><p>Shares of Rani Therapeutics Holdings, Inc. (NASDAQ:RANI - Get Free Report) rose 1.3% during mid-day trading on Friday . The stock traded as high as $1.6650 and last traded at $1.59. Approximately 2,328,448 shares traded hands during trading, a decline of 28% from the average daily volume of 3,241,141 shares. The stock had previously closed at $1.57.</p><div><p><span></span><span>Get <strong>Rani Therapeutics</strong> alerts:</span></p></div><h2>Wall Street Analysts Forecast Growth</h2><p>A number of research firms have commented on RANI. Maxim Group boosted their target price on Rani Therapeutics from $5.00 to $10.00 and gave the stock a &#34;buy&#34; rating in a research report on Monday, October 20th. Weiss Ratings  reaffirmed a &#34;sell (d-)&#34; rating on shares of Rani Therapeutics in a research note on Tuesday. HC Wainwright  reissued a &#34;buy&#34; rating and issued a $11.00 price objective on shares of Rani Therapeutics in a research note on Tuesday, October 21st. Finally, Wall Street Zen upgraded shares of Rani Therapeutics from a &#34;sell&#34; rating to a &#34;hold&#34; rating in a research report on Saturday, August 16th. Four research analysts have rated the stock with a Buy rating and one  has given a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of &#34;Moderate Buy&#34; and an average price target of $8.50.</p><p><b>Get Our Latest Report on Rani Therapeutics</b></p><h2>Rani Therapeutics Stock Performance</h2><p>The company has a market capitalization of $193.20 million, a PE ratio of -2.01 and a beta of 0.40. The stock's fifty day simple moving average is $1.49 and its 200-day simple moving average is $0.87. </p><p>Rani Therapeutics (NASDAQ:RANI - Get Free Report) last posted its quarterly earnings data on Thursday, November 6th. The company reported ($0.12) earnings per share for the quarter, missing analysts' consensus estimates of ($0.09) by ($0.03).  On average, equities analysts anticipate that  Rani Therapeutics Holdings, Inc. will post -1.01 EPS for the current year. </p><h2>Insiders Place Their Bets</h2><p>In other news, major shareholder South Cone Investments Limited sold 4,000,000 shares of the firm's stock in a transaction on Tuesday, October 21st. The stock was sold at an average price of $2.77, for a total transaction of $11,080,000.00. Following the sale, the insider owned 2,379,194 shares in the company, valued at $6,590,367.38. This trade represents a 62.70% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities &amp; Exchange Commission, which is available through this link. Also, Director Mir A. Imran bought 2,083,334 shares of Rani Therapeutics stock in a transaction that occurred on Thursday, October 23rd. The shares were acquired at an average price of $0.60 per share, for a total transaction of $1,250,000.40. Following the completion of the transaction, the director directly owned 2,083,334 shares of the company's stock, valued at $1,250,000.40. This trade represents a ∞ increase in their position. The SEC filing for this purchase provides additional information. Corporate insiders own  45.08% of the company's stock. </p><h2>Institutional Investors Weigh In On Rani Therapeutics</h2><p>Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. King Luther Capital Management Corp raised its holdings in shares of  Rani Therapeutics by 75.8% in the 1st quarter. King Luther Capital Management Corp now owns 58,000 shares of the company's stock worth $73,000 after purchasing an additional 25,000 shares during the period.  Janney Montgomery Scott LLC raised its holdings in  Rani Therapeutics by 102.9% in the second quarter. Janney Montgomery Scott LLC now owns 55,200 shares of the company's stock valued at $28,000 after buying an additional 28,000 shares during the period.  Well Done LLC acquired a new position in  Rani Therapeutics during the second quarter valued at approximately $27,000.  CWA Asset Management Group LLC grew its stake in  Rani Therapeutics by 80.0% during the third quarter. CWA Asset Management Group LLC now owns 150,000 shares of the company's stock worth $75,000 after buying an additional 66,667 shares during the period.  Finally, Kestra Private Wealth Services LLC grew its stake in  Rani Therapeutics by 44.8% during the third quarter. Kestra Private Wealth Services LLC now owns 226,142 shares of the company's stock worth $113,000 after buying an additional 70,002 shares during the period. 30.19% of the stock is currently owned by institutional investors and hedge funds. </p><h2>Rani Therapeutics Company Profile</h2> (Get Free Report)<p>Rani Therapeutics Holdings, Inc operates as a clinical stage biotherapeutics company that develops orally administered biologics for patients, physicians, and healthcare systems in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies.</p><h2>Featured Articles</h2><ul><li>Five stocks we like better than Rani Therapeutics</li><li>Where to Find Earnings Call Transcripts</li><li>Rocket Lab’s Big Rebound? Analysts Suggest the Dip's a Gift</li><li>High Dividend REITs: Are They an Ideal Way to Diversify?</li><li>Meta’s AI Moment? New SAM 3 Model Has Wall Street Turning Bullish</li><li>What is the Hang Seng index?  </li><li>Snowflake Stock: The Dip That Smart Investors Are Buying Right Now</li></ul><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Rani Therapeutics Right Now?</h2><p>Before you consider Rani Therapeutics, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Rani Therapeutics wasn't on the list.</p><p>While Rani Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

RANI

<p>Rani Therapeutics' stock rose 1.3% amid trading volume decline. Analysts have mixed ratings, with Maxim Group raising the target price to $10 and HC Wainwright setting it at $11. Insider trading included a major shareholder selling 4 million shares and a director buying over 2 million shares. Institutional investors have adjusted their stakes, with some increasing holdings significantly. The company, focused on oral biologics delivery, has a market cap of $193.20 million and a PE ratio of -2.01.</p>

Rani Therapeutics (NASDAQ:RANI) Stock Price Up 1.3% - Here's Why